嘉应制药
(002198)
| 流通市值：31.82亿 | | | 总市值：31.82亿 |
| 流通股本：5.07亿 | | | 总股本：5.08亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 198,937,664.09 | 121,632,944.06 | 376,167,156.57 | 259,604,624.04 |
| 营业收入 | 198,937,664.09 | 121,632,944.06 | 376,167,156.57 | 259,604,624.04 |
| 二、营业总成本 | 174,323,616.04 | 101,544,275.2 | 349,185,997.89 | 256,532,928.46 |
| 营业成本 | 74,509,094.31 | 40,369,560.36 | 150,722,980.96 | 110,541,535.59 |
| 税金及附加 | 3,394,073.61 | 1,962,224.32 | 7,188,491.9 | 4,793,445.6 |
| 销售费用 | 72,435,897.48 | 44,206,430.98 | 137,401,217.09 | 103,992,488.16 |
| 管理费用 | 19,460,130.48 | 13,474,828.62 | 48,485,607.56 | 32,779,996.48 |
| 研发费用 | 4,813,656.5 | 1,699,113.63 | 6,757,234.58 | 5,583,739.76 |
| 财务费用 | -289,236.34 | -167,882.71 | -1,369,534.2 | -1,158,277.13 |
| 其中:利息费用 | - | - | 3,955.04 | - |
| 其中:利息收入 | 318,516.76 | 182,881.75 | 1,408,500.11 | 1,182,665.06 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -361,667.6 | -499,543 | - | 127,440.66 |
| 加:投资收益 | 415,663.13 | -352,280 | 675,010.43 | 590,765.52 |
| 资产处置收益 | 120.92 | 120.92 | 1,606,951.4 | 1,606,951.4 |
| 资产减值损失(新) | - | - | -1,190,339.63 | -854,420.55 |
| 信用减值损失(新) | -1,296,086.72 | - | -4,030,242.59 | -353,872.07 |
| 其他收益 | 129,182.39 | 90,263.76 | 1,215,061.69 | 525,226.87 |
| 四、营业利润 | 23,501,260.17 | 19,327,230.54 | 25,257,599.98 | 4,713,787.41 |
| 加:营业外收入 | 165,617.82 | 99,002.13 | 291,258.51 | 271,919.19 |
| 减:营业外支出 | 69,002.13 | 86,919.96 | 453,781.12 | 178,372.42 |
| 五、利润总额 | 23,597,875.86 | 19,339,312.71 | 25,095,077.37 | 4,807,334.18 |
| 减:所得税费用 | 3,515,316.38 | 3,936,055.53 | 4,483,477.82 | 1,933,988.23 |
| 六、净利润 | 20,082,559.48 | 15,403,257.18 | 20,611,599.55 | 2,873,345.95 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 20,082,559.48 | 15,403,257.18 | 20,611,599.55 | 2,873,345.95 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 20,082,559.48 | 15,403,257.18 | 20,611,599.55 | 2,873,345.95 |
| 扣除非经常损益后的净利润 | 18,788,637.68 | 15,751,018.59 | 14,552,294.96 | -1,879,039.02 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.04 | 0.03 | 0.04 | 0.01 |
| (二)稀释每股收益 | 0.04 | 0.03 | 0.04 | 0.01 |
| 八、其他综合收益 | -1,062,500 | - | - | - |
| 归属于母公司股东的其他综合收益 | -1,062,500 | - | - | - |
| 九、综合收益总额 | 19,020,059.48 | 15,403,257.18 | 20,611,599.55 | 2,873,345.95 |
| 归属于母公司股东的综合收益总额 | 19,020,059.48 | 15,403,257.18 | 20,611,599.55 | 2,873,345.95 |
| 公告日期 | 2025-08-26 | 2025-04-26 | 2025-04-26 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |